Conference Coverage

Human Amyloid Imaging 2025

San Juan, Puerto Rico

–

After 14 years in Miami, HAI is on the move again. This January conference started in chilly Boston and moved around the north for some time, meeting in Chicago, Seattle, and Toronto, before settling in a warmer clime in 2011. For 2025, HAI pulled up stakes again and landed in San Juan, Puerto Rico. There, 419 attendees from 16 countries shared data about how to line up blood biomarkers with PET data, how locus coeruleus connectivity might influence tangle spread, and what the field is learning from its growing focus on studying non-white populations. 

  1. Studying Diverse Populations May Require New Biomarkers
  2. When Tau Wanders Off, Subcortical Axon Firing Goes Mum
  3. At Human Amyloid Imaging Conference, Plasma Tau Was the Star

Clinical Trials on Alzheimer's Disease (CTAD) 2024 - 17th

Madrid, Spain

–

Last month in Madrid, researchers traded news about clinical trials for Alzheimer’s disease. The field is watching the rollout of lecanemab and donanemab with bated breath, debating administration, appropriate use, and hoping for no more deaths. Soon after, European regulators issued a thumbs up for lecanemab. Meanwhile, brain shuttle versions are on the horizon, led by trontinemab. Tau as a target is starting to yield to antibodies, though OGA inhibition currently appears too toxic.

View all 12 articles on this conference

AD/PD™ 2024: Advances in Science & Therapy

Lisbon, Portugal and Online

–

The port city of Lisbon, the launch point of many a voyage of exploration, seemed a fitting site to host the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. Disease-modifying therapies for amyloid plaques now approved, researchers are searching for similar treatments for tau, synuclein, and other potential drivers of neurodegeneration. With more than 4,700 attendees navigating 600+ presentations during five days, often spread across six parallel sessions, the conference was bustling, yet imbued with a sense of discovery. Speakers discussed new small-molecule and antibody therapies, combination approaches, new plasma biomarkers for tau and TDP43, and a good smattering of basic biology, from cellular resilience to microglial diversity. Follow along with Alzforum’s conference coverage.

View all 9 articles on this conference

Holloway Summit 2023: FTD Biomarkers

Miami Beach, Florida

–

To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a recent conference in Miami, speakers showed data on potential fluid biomarkers and PET tracers that could differentiate the two main proteinopathies, tau and TDP-43. They also discussed nascent markers and debuted an AI algorithm that improves the diagnostic capabilities of FDG-PET scans.

View all 2 articles on this conference